Granite Investment Partners LLC reduced its position in Celgene Co. (NASDAQ:CELG) by 0.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,424 shares of the biopharmaceutical company’s stock after selling 33 shares during the period. Granite Investment Partners LLC’s holdings in Celgene were worth $675,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the company. Duncker Streett & Co. Inc. raised its position in shares of Celgene by 6.5% in the first quarter. Duncker Streett & Co. Inc. now owns 6,915 shares of the biopharmaceutical company’s stock valued at $860,000 after buying an additional 420 shares during the period. First Mercantile Trust Co. raised its position in shares of Celgene by 24.9% in the first quarter. First Mercantile Trust Co. now owns 58,047 shares of the biopharmaceutical company’s stock valued at $7,223,000 after buying an additional 11,565 shares during the period. First Quadrant L P CA raised its position in shares of Celgene by 20.4% in the first quarter. First Quadrant L P CA now owns 101,816 shares of the biopharmaceutical company’s stock valued at $12,669,000 after buying an additional 17,273 shares during the period. NBT Bank N A NY raised its position in shares of Celgene by 84.1% in the first quarter. NBT Bank N A NY now owns 20,219 shares of the biopharmaceutical company’s stock valued at $2,516,000 after buying an additional 9,238 shares during the period. Finally, First Citizens Bank & Trust Co. raised its position in shares of Celgene by 2.2% in the first quarter. First Citizens Bank & Trust Co. now owns 11,669 shares of the biopharmaceutical company’s stock valued at $1,451,000 after buying an additional 255 shares during the period. Institutional investors own 77.68% of the company’s stock.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Celgene Co. (NASDAQ:CELG) opened at 116.78 on Friday. Celgene Co. has a one year low of $94.42 and a one year high of $127.64. The company’s 50-day moving average is $121.62 and its 200 day moving average is $119.73. The company has a market capitalization of $91.18 billion, a P/E ratio of 43.85 and a beta of 1.74.

Celgene (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, April 27th. The biopharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.47 by $0.21. The firm had revenue of $2.96 billion for the quarter, compared to the consensus estimate of $3.04 billion. Celgene had a net margin of 17.80% and a return on equity of 77.95%. The business’s revenue for the quarter was up 17.8% on a year-over-year basis. During the same period in the prior year, the company posted $1.32 earnings per share. Analysts predict that Celgene Co. will post $7.28 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/05/28/celgene-co-celg-shares-sold-by-granite-investment-partners-llc.html.

Several research analysts have recently commented on CELG shares. Cann restated an “outperform” rating and set a $148.00 price target on shares of Celgene in a research note on Friday, February 24th. Mizuho set a $130.00 price target on shares of Celgene and gave the stock a “buy” rating in a research note on Sunday, February 19th. Robert W. Baird restated an “outperform” rating and set a $162.00 price target on shares of Celgene in a research note on Wednesday, April 19th. Oppenheimer Holdings Inc. restated an “outperform” rating and set a $148.00 price target (up previously from $141.00) on shares of Celgene in a research note on Monday, January 30th. Finally, Jefferies Group LLC increased their price target on shares of Celgene from $147.00 to $155.00 and gave the stock a “buy” rating in a research note on Tuesday, February 28th. One analyst has rated the stock with a sell rating, six have issued a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the stock. Celgene currently has an average rating of “Buy” and a consensus target price of $138.89.

In other Celgene news, insider Rupert Vessey sold 4,000 shares of the stock in a transaction dated Wednesday, March 1st. The shares were sold at an average price of $124.42, for a total transaction of $497,680.00. Following the sale, the insider now directly owns 778 shares in the company, valued at $96,798.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director James J. Loughlin sold 9,250 shares of the stock in a transaction dated Monday, May 1st. The stock was sold at an average price of $124.00, for a total transaction of $1,147,000.00. Following the sale, the director now owns 32,169 shares in the company, valued at $3,988,956. The disclosure for this sale can be found here. Insiders have sold 27,283 shares of company stock worth $3,382,386 over the last quarter. Corporate insiders own 0.97% of the company’s stock.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

12 Month Chart for NASDAQ:CELG

Receive News & Stock Ratings for Celgene Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Co. and related stocks with our FREE daily email newsletter.